https://scholars.lib.ntu.edu.tw/handle/123456789/540307
標題: | Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: An update | 作者: | YUNG-MING CHEN WEN-CHIH CHIANG SHUEI-LIONG LIN TUN-JUN TSAI |
公開日期: | 2017 | 出版社: | BioMed Central Ltd. | 卷: | 24 | 期: | 1 | 起(迄)頁: | 84 | 來源出版物: | Journal of Biomedical Science | 摘要: | Blood pressure control with renin-angiotensin system (RAS) blockade has remained the gold standard for treating patients with proteinuric chronic kidney disease (CKD) up to date. Nevertheless, RAS blockade slows but does not halt the progression of kidney disease, thus highlighting the need to search for additional therapeutic approaches. The nonselective phosphodiesterase (PDE) inhibitor pentoxifylline (PTX) is an old drug that exhibits prominent anti-inflammatory, anti-proliferative and anti-fibrotic activities both in vitro and in vivo. Studies in human subjects have shown that PTX monotherapy decreases urinary protein excretion, and add-on therapy of PTX to background RAS blockade additively reduces proteinuria in patients with CKD of various etiology. More recent studies find that PTX combined with RAS blockade delays the decline of glomerular filtration rate in diabetic patients with mild to moderate CKD, and reduces the risk of end-stage renal disease in diabetic and non-diabetic patients in late stage of CKD with high proteinuria levels. In this review, we update the clinical trial results of PTX as monotherapy, or in conjunction or in comparison with RAS blockade on patients with proteinuria and CKD, and propose a mechanistic scheme explaining the renoprotective activities of this drug. ? 2017 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034035544&doi=10.1186%2fs12929-017-0390-4&partnerID=40&md5=c4dc19e8fb294e4c2e457fb109c107ba https://scholars.lib.ntu.edu.tw/handle/123456789/540307 |
ISSN: | 1021-7770 | DOI: | 10.1186/s12929-017-0390-4 | SDG/關鍵字: | angiotensin receptor antagonist; calcineurin inhibitor; captopril; corticosteroid; creatinine; dipeptidyl carboxypeptidase inhibitor; enalapril; losartan; monocyte chemotactic protein 1; mycophenolate mofetil; nephrin; pentoxifylline; placebo; tumor necrosis factor; pentoxifylline; phosphodiesterase inhibitor; abdominal discomfort; add on therapy; albuminuria; antihypertensive activity; antiinflammatory activity; antiproliferative activity; bleeding; cardiovascular disease; cerebrovascular accident; cerebrovascular disease; chronic kidney failure; coughing; creatinine blood level; creatinine clearance; diabetes mellitus; diabetic nephropathy; diarrhea; disease course; disease severity; dizziness; drug dose reduction; drug efficacy; drug indication; drug metabolism; drug safety; drug tolerability; drug withdrawal; dry cough; dyspepsia; dyspnea; end stage renal disease; flatulence; gastric ulcer bleeding; gastroesophageal reflux; gastrointestinal symptom; glomerulus filtration rate; headache; human; macroalbuminuria; menorrhagia; microalbuminuria; monotherapy; nausea; nausea and vomiting; nonhuman; pathophysiology; priority journal; protein secretion; proteinuria; renal protection; renin angiotensin aldosterone system; retina hemorrhage; Review; risk reduction; thorax pain; urinary excretion; vomiting; chronic kidney failure; disease exacerbation; proteinuria; urine; Disease Progression; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinuria; Renal Insufficiency, Chronic |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。